SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAI

I

	Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES I
U	Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of th

TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	(OVAL							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

1. Name and Address of Reporting Person [*] Ausiello Dennis A			2. Issuer Name and Ticker or Trading Symbol Seres Therapeutics, Inc. [MCRB]		tionship of Reporting Perso all applicable) Director	n(s) to Issuer 10% Owner	
C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET		()	3. Date of Earliest Transaction (Month/Day/Year) 06/15/2016		Officer (give title below)	Other (specify below)	
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	ndividual or Joint/Group Filing (Check Applicable		
(Street) CAMBRIDGE (City)	MA (State)	02139 (Zip)		X	Form filed by One Repor Form filed by More than Person	0	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		Date, Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date	3A. Deemed Execution Date,	4. Transa		5. Numb		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities		8. Price of Derivative	derivative	10. Ownership	11. Nature of Indirect
Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Year)	if any (Month/Day/Year)	Code (8)	insu.	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		(Month/Day/Year)		Underlying Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$30.24	06/15/2016		A		15,000		(1)	06/14/2026	Common Stock	15,000	\$0.00	15,000	D	

Explanation of Responses:

1. The option vests in full on the earlier of June 15, 2017 or the day immediately prior to the company's 2017 annual meeting of shareholders.

Remarks:

<u>/s/ Roger J. Pomerantz,</u> <u>Attorney-in-Fact</u>

06/17/2016

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.